Takeda Pharma Says Phase 2 ELEKTRA Study Of Soticlestat Met Primary Endpoint

Japanese drug maker Takeda Pharmaceutical Co. Limited (TAK) and biopharmaceutical company Ovid Therapeutics Inc. (OVID) said that the randomized Phase 2 ELEKTRA study of Soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) met the primary endpoint of reducing seizure frequency in the children.

from RTT - Biotech https://ift.tt/3jdQczr
via IFTTT